Dendreon financially commits to providing contract manufacturing and patient services

Dendreon Pharmaceuticals, a commercial-stage biopharma company, has established and invested in its new contract manufacturing and services division to help bring late-stage clinical assets through to commercialization. The company now offers end-to-end manufacturing of complex cell therapies and patient logistics for partner programs, as a result of its manufacturing, process development and logistics capabilities.

“Innovative cell therapies have the potential to change how we treat serious diseases, but there is currently insufficient capacity to meet anticipated industry demand,” notes Jason O’Neill, Dendreon’s CEO. “With more than a decade of proven expertise in cell therapy manufacturing and an established supply chain and logistics infrastructure, we have invested in an offering that fills an immediate market need in this rapidly expanding field. This is a significant accomplishment for Dendreon and plays a key role in our future growth plans.”

According to the company, it is one of only four organizations manufacturing cell therapies for commercial use in the US. Dendreon's 180,000+ square foot cGMP (current good manufacturing practice)-compliant and FDA approved manufacturing facility in Seal Beach, CA, will be the contract manufacturing services hub, while the Seattle location will serve as the process development and manufacturing sciences center.